Table 1 shows the two-dimensional similarities of 15 identified novel compounds. The purpose of this study was to determine and analyse the antiangiogenic, antimigratory and antiproliferative potency of the two most potent antiangiogenic and antiproliferative compounds, named HP-2 and HP-14. Evidence for the specific VEGFR-2 inhibition by the novel compounds in terms of binding properties and VEGFR-2-related inhibition of tumour cell growth was already shown in a previous study (Schmidt et al, 2008). The gene discussed is KDR; the disease is neoplasm.